Release Date: September 29, 2017
Expiration Date: September 30, 2018 (subject to change)
- CE for this activity will not be available after this date.
Reference Number: 17022545
This interactive CE activity demonstrates the necessity to screen patients in the general adult population for depressive disorders to ensure accurate diagnosis, effective treatment and appropriate follow-up. Even with guideline-based treatment, cognitive dysfunction in major depressive disorder often persists and goes unevaluated and untreated. Experts will discuss and demonstrate how the use of evidence based screening tools and patient-centered shared decision-making can effectively improve health outcomes by addressing residual symptoms and improving adherence of treatment plans.
CE Credit Instructions
- Read this activity description, including objectives and disclosures.
- Complete the educational content completely:
- Video Presentations: Watch all video presentations completely.
- Review all additional materials provided (handouts, posttest reviews, any other downloadable resources).
- After completing all content, go to Steps to Receive Credit to complete the posttest and evaluation to receive full AANP CE/Rx credit. If other types of credit are offered, these options will be available after completing the activity evaluation.
Upon completion of this activity, the participant should be able to:
- Implement prompt screening, diagnosing and treatment interventions for patients with MDD to improve health outcomes.
- Discuss current knowledge and guidelines on treatment steps for MDD including treatment-resistant depression individualized to patient characteristics to increase health outcomes for patients with MDD.
- Discuss current knowledge and evidence-based recommendations on assessing and monitoring cognition through use of validated screening tools in patients with MDD prior and during therapeutic treatment.
- Recommend therapeutic options individualized to patient characteristics when cognitive functioning needs improvement in MDD patients.
- Discuss current knowledge and SDM strategies for improving patient psycho-education and medication adherence individualized to patient characteristics to increase health outcomes for patients with MDD.
Susie Adams PhD, PMHNP, FAANP, FAAN
Luann Richardson PhD, FNP, GNP, PMHNP, FAANP
This activity was developed in accordance with AANP Accreditation Standards and Policies. It is supported by educational funding provided by Takeda Pharmaceuticals U.S.A, Inc. and Lundbeck.
Dr. Adams and Dr. Richardson have no relevant affiliations to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. It may contain opinions of the speakers from their personal experience.
Post Impact Survey:
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to all learners to participate in a Post Impact Outcomes Survey (PI Survey). Participation in the survey is optional and does not affect the credit earned. The PI surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.